Adicet Bio CSO has shares withheld for taxes

Adicet Bio's Chief Scientific Officer, Aftab Blake, reported a routine share withholding related to equity compensation.

Rhea-AI Filing Summary

Adicet Bio's Chief Scientific Officer, Aftab Blake, reported a routine share withholding related to equity compensation. On January 24, 2026, 535 shares of common stock were withheld at $8.44 per share to cover tax obligations arising from the vesting of restricted stock units, and this did not involve an open-market sale. Following this withholding, Blake directly beneficially owned 2,981 shares of Adicet Bio common stock. The reported holdings also reflect a 1-for-16 reverse stock split that Adicet Bio effected on December 30, 2025.

Insider Trade Summary

Exercise Price or Tax Liability: 535 shares

Exercise Price or Tax Liability 1 txn

Insider Aftab Blake

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	535	$8.44	$5K

Holdings After Transaction: Common Stock — 2,981 shares (Direct)

Footnotes (2)

1. F1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
2. F2. Reflects a 1-for-16 reverse stock split effected by the Issuer on December 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Adicet Bio (ACET) disclose for Aftab Blake?

Adicet Bio reported that Chief Scientific Officer Aftab Blake had 535 shares of common stock withheld on January 24, 2026 to cover tax obligations from vested restricted stock units, rather than selling shares in the open market.

Did Adicet Bio (ACET) Chief Scientific Officer sell shares in this Form 4?

No, the Form 4 states the 535 shares of common stock were withheld for tax withholding obligations related to vesting restricted stock units, and explicitly notes this does not represent a sale by Chief Scientific Officer Aftab Blake.

How many Adicet Bio (ACET) shares does Aftab Blake hold after the reported transaction?

After the tax withholding transaction, Chief Scientific Officer Aftab Blake directly beneficially owned 2,981 shares of Adicet Bio common stock. This figure incorporates prior adjustments, including the company’s reverse stock split noted in the filing.

What was the price used for the Adicet Bio (ACET) tax withholding shares?

The Form 4 shows that the 535 shares withheld for taxes were valued at $8.44 per share. This price is used to calculate the value of shares applied toward satisfying Blake’s equity-related tax withholding obligations.

How does the reverse stock split affect the Adicet Bio (ACET) Form 4 figures?

The filing explains that the reported holdings reflect a 1-for-16 reverse stock split Adicet Bio effected on December 30, 2025, meaning all share amounts shown, including the 2,981 shares beneficially owned, are already adjusted for that split.

What role does Aftab Blake hold at Adicet Bio (ACET) in this Form 4?

In this Form 4, Aftab Blake is identified as an officer of Adicet Bio, serving as Chief Scientific Officer. The reported equity transaction and resulting share ownership relate to this executive role at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 04:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aftab Blake

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/24/2026		F(1)		535	D	$8.44	2,981(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

2. Reflects a 1-for-16 reverse stock split effected by the Issuer on December 30, 2025.

	/s/ Nick Harvey, Attorney-in-Fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.